Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial
Guo X, Lou W, Xu Y, Zhuang R, Yao L, Wu J, Fu D, Zhang J, Liu J, Rong Y, Jin D, Wu W, Xu X, Ji Y, Wu L, Lv M, Yao X, Liu X, Wang D, Kuang T, Liu L, Wang W, Liu T, Zhou Y. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. Oncology Letters 2024, 27: 161. PMID: 38449794, PMCID: PMC10915801, DOI: 10.3892/ol.2024.14293.Peer-Reviewed Original ResearchProgression-free survivalAdvanced pancreatic cancerC-reactive proteinPancreatic cancerAS regimenNab-paclitaxelAdvanced PCPrimary endpointGene mutationsEfficacy of nab-paclitaxelPatients treated with GSSafety of nab-paclitaxelMedian progression-free survivalMedian follow-up timePhase II randomized trialC-reactive protein levelsHigh C-reactive proteinImproved overall survivalSubsets of patientsFollow-up timeCost-effective treatment regimenOS benefitData cutoffOpen-labelOverall survival